MindWalk Holdings (HYFT) Shares Outstanding (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Shares Outstanding (Entity) of $46.7 million for Q2 2026, up 39.92% year-over-year from $33.4 million in Q2 2025, and little changed quarter-over-quarter from $46.7 million in Q1 2026.
MindWalk Holdings (HYFT) Shares Outstanding (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Shares Outstanding (Entity) for 7 consecutive years, with $46.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 39.92% year-over-year to $46.7 million; the TTM figure through Apr 2026 stood at $46.7 million (up 39.92% YoY), while the FY2026 annual figure was $46.7 million, up 39.92% from the prior year.
- Shares Outstanding (Entity) held at $46.7 million in Q2 2026 per HYFT's latest filing, from $46.7 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $25.1 billion in Q4 2023 and bottomed at $19.7 million in Q2 2022.
- Historically, Shares Outstanding (Entity) has averaged $5.3 billion across 5 years, with a median of $33.1 million in 2025.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) tumbled 99.9% — and 2025, when it jumped 69.05%.
- MindWalk Holdings' Shares Outstanding (Entity) stood at $24.9 billion in 2022, then increased by 0.71% to $25.1 billion in 2023, then sank by 99.88% to $30.3 million in 2024, then surged by 52.39% to $46.2 million in 2025, then grew by 1.2% to $46.7 million in 2026.
- Business Quant data shows HYFT's Shares Outstanding (Entity) at $46.7 million in Q2 2026, $46.7 million in Q1 2026, and $46.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 720.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 46.38 Mn |
| Jan 31, 2026 | 46.52 Mn |
| Oct 31, 2025 | 46.16 Mn |
| Jul 31, 2025 | 46.15 Mn |
| Apr 30, 2025 | 33.39 Mn |
| Jan 31, 2025 | 32.85 Mn |
| Oct 31, 2024 | 28.13 Mn |
| Jul 31, 2024 | 27.13 Mn |
| Apr 30, 2024 | 25.64 Mn |
| Jan 31, 2024 | 25.80 Mn |
| Oct 31, 2023 | 25.05 Bn |
| Jul 31, 2023 | 25.05 Mn |
| Apr 30, 2023 | 24.90 Mn |
| Jan 31, 2023 | 24.94 Mn |
| Oct 31, 2022 | 24.87 Bn |
| Jul 31, 2022 | 24.74 Bn |
| Apr 30, 2022 | 19.69 Mn |
| Jan 31, 2022 | 19.43 Bn |
| Oct 31, 2021 | 19.34 Bn |
| Jul 31, 2021 | 19.22 Bn |